As a remission induction therapy in patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), the therapeutic efficacy of mycophenolate mofetil (MMF) is similar to that of cyclophosphamide, according to a meta-analysis of data from four randomized controlled trials. In the studies, which enrolled a total of 300 patients with AAV, MMF and cyclophosphamide led to similar rates of remission at 6 months, ANCA negativity at 6 months and long-term relapse. Rates of death among patients with AAV were similar with both treatments.
References
Original article
Kuzuya, K. et al. Efficacy of mycophenolate mofetil as a remission induction therapy in antineutrophil cytoplasmic antibody: associated vasculitis — a meta-analysis. RMD Open 6, e001195 (2020)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Onuora, S. MMF comparable to cyclophosphamide in AAV. Nat Rev Rheumatol 16, 350 (2020). https://doi.org/10.1038/s41584-020-0440-2
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41584-020-0440-2